Alvotech Lines Up US Biosimilar Approvals After FDA Inspection

AVT02 Adalimumab And AVT04 Ustekinumab Approvals Expected Early This Year

 
• By David Wallace
Calendar showing February to April 2024
Alvotech said it expects approvals in early 2024 • Source: Shutterstock

More from Biosimilars

More from Products